Hyloris Pharmaceuticals SA (FRA:52U)
Germany · Delayed Price · Currency is EUR 7.96
+0.50 (6.70%)
At close: Jan 23, 2026
Hyloris Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7.32 | 8.46 | 2.09 | 0.9 | 3.1 | 0.18 |
Other Revenue | 1.14 | 1.3 | 1.67 | 1.49 | - | - |
| 8.46 | 9.76 | 3.76 | 2.39 | 3.1 | 0.18 | |
Revenue Growth (YoY) | 30.42% | 159.64% | 57.48% | -22.90% | 1669.14% | 92.31% |
Cost of Revenue | 0.25 | 0.23 | 0.09 | 0.09 | 0.11 | 0.15 |
Gross Profit | 8.21 | 9.53 | 3.67 | 2.29 | 2.99 | 0.03 |
Selling, General & Admin | 4.68 | 5.63 | 5.55 | 3.52 | 2.9 | 2.19 |
Research & Development | 9.93 | 10.27 | 14.42 | 10.27 | 5.03 | 2.93 |
Other Operating Expenses | -0.43 | 0.01 | -0.46 | 0.01 | 5.38 | -0.02 |
Operating Expenses | 14.17 | 15.9 | 19.51 | 13.8 | 13.31 | 5.11 |
Operating Income | -5.96 | -6.37 | -15.85 | -11.51 | -10.33 | -5.08 |
Interest Expense | -0.6 | -0.08 | -0.05 | -0.22 | -0.56 | -0.84 |
Interest & Investment Income | 0.75 | 0.9 | 0.87 | 0.07 | 0.03 | 0.01 |
Earnings From Equity Investments | -0.05 | -0.08 | -0.15 | -0.13 | -0.19 | - |
Currency Exchange Gain (Loss) | 0.26 | 0.26 | 0.02 | 0.35 | -0.19 | 0.28 |
Other Non Operating Income (Expenses) | -0.29 | -0.3 | -0.22 | -0.23 | -0.03 | -1.57 |
EBT Excluding Unusual Items | -5.89 | -5.66 | -15.38 | -11.68 | -11.26 | -7.2 |
Gain (Loss) on Sale of Investments | -0.97 | -0.97 | - | - | - | - |
Asset Writedown | - | - | - | - | -0.02 | -0.48 |
Legal Settlements | 0.29 | 0.29 | - | - | - | - |
Other Unusual Items | - | - | - | -0.23 | - | 0.53 |
Pretax Income | -6.57 | -6.34 | -15.38 | -11.9 | -11.28 | -7.14 |
Income Tax Expense | -0.16 | - | - | 0 | 0.3 | 0 |
Earnings From Continuing Operations | -6.41 | -6.34 | -15.38 | -11.91 | -11.58 | -7.15 |
Net Income | -6.41 | -6.34 | -15.38 | -11.91 | -11.58 | -7.15 |
Net Income to Common | -6.41 | -6.34 | -15.38 | -11.91 | -11.58 | -7.15 |
Shares Outstanding (Basic) | 27 | 28 | 28 | 27 | 26 | 22 |
Shares Outstanding (Diluted) | 27 | 28 | 28 | 27 | 26 | 22 |
Shares Change (YoY) | -4.61% | - | 2.95% | 5.29% | 18.40% | 51.63% |
EPS (Basic) | -0.24 | -0.23 | -0.55 | -0.44 | -0.45 | -0.33 |
EPS (Diluted) | -0.24 | -0.23 | -0.55 | -0.44 | -0.45 | -0.33 |
Free Cash Flow | -6.9 | -6.93 | -13.11 | -13.12 | -11.36 | -4.57 |
Free Cash Flow Per Share | -0.25 | -0.25 | -0.47 | -0.48 | -0.44 | -0.21 |
Gross Margin | 97.08% | 97.67% | 97.53% | 96.06% | 96.54% | 17.14% |
Operating Margin | -70.47% | -65.26% | -421.55% | -482.11% | -333.50% | -2900.57% |
Profit Margin | -75.80% | -64.98% | -409.15% | -498.78% | -374.00% | -4082.86% |
Free Cash Flow Margin | -81.55% | -71.03% | -348.66% | -549.69% | -366.83% | -2611.43% |
EBITDA | -5.81 | -6.22 | -15.67 | -11.43 | -10.27 | -5.03 |
EBITDA Margin | -68.66% | -63.70% | - | - | - | - |
D&A For EBITDA | 0.15 | 0.15 | 0.18 | 0.08 | 0.05 | 0.05 |
EBIT | -5.96 | -6.37 | -15.85 | -11.51 | -10.33 | -5.08 |
EBIT Margin | -70.47% | -65.26% | - | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.